# Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia

> **NCT06973356** · NA · RECRUITING · sponsor: **Anhui Provincial Hospital** · enrollment: 18 (estimated)

## Conditions studied

- Immune Thrombocytopenia (ITP)

## Interventions

- **DRUG:** Anti-CD19/BCMA CAR gene vector injection will be injected intravenously on a one-time basis.

## Key facts

- **NCT ID:** NCT06973356
- **Lead sponsor:** Anhui Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-16
- **Primary completion:** 2029-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06973356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06973356, "Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06973356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*